• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Alnylam Pharmaceuticals Inc.

    4/4/25 4:30:17 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNY alert in real time by email
    DEFA14A 1 alny2025proxyamendment.htm DEFA14A Document

     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. 1)
     
     
    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐
    Check the appropriate box:
     
    ☐Preliminary Proxy Statement
     
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) 
     
    ☐Definitive Proxy Statement
     
    ☒  Definitive Additional Materials
     
    ☐    Soliciting Material under §240.14a-12 
    Alnylam Pharmaceuticals, Inc.
    image_0.jpg
    (Name of Registrant as Specified in Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
     
    ☒No fee required
     



    ☐Fee paid previously with preliminary materials
     
    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 
     
     
     
    AMENDMENT NO. 1 TO PROXY STATEMENT
    FOR THE ANNUAL MEETING OF STOCKHOLDERS
    TO BE HELD ON MAY 8, 2025
    This Amendment No.1 to the Proxy Statement (this “Amendment”) amends the definitive proxy statement filed by Alnylam Pharmaceuticals, Inc. (the “Company”) with the U.S. Securities and Exchange Commission (“SEC”) on March 24, 2025 (the “Proxy Statement”) and made available to the Company’s stockholders in connection with the solicitation of proxies by the Company’s Board of Directors (the “Board”) for use at the Company’s Annual Meeting of Stockholders, scheduled to be held on May 8, 2025 at 8:30 A.M. (Eastern Time) (the “Annual Meeting”). This Amendment is being filed with the SEC on April 4, 2025.
    This Amendment clarifies certain disclosure in the Proxy Statement on the vote requirements for Proposal 2, “To approve an amendment to our Restated Certificate of Incorporation allowing for officer exculpation” (“Proposal 2”). The vote required to approve Proposal 2 is the approval of a majority of the outstanding shares of common stock of the Company. Abstentions and broker non-votes, if any, will have the same effect as a vote “Against” Proposal 2.
    Except as specifically amended herein, all information in the Proxy Statement remains unchanged. No other changes have been made to the Proxy Statement. If you have already returned your proxy card or provided voting instructions, you do not need to take any action unless you wish to change your vote. This Amendment should be read in conjunction with the Proxy Statement. 
    ******
    The description of the vote required to approve Proposal 2 on page 71 of the Proxy Statement under the heading “Vote Required” is hereby amended and restated in its entirety as follows:
    The affirmative vote of the holders of a majority of the outstanding shares of our common stock is required to approve the Charter Amendment. Abstentions and broker non-votes, if any, will have the same effect as a vote “Against” Proposal 2. If the proposed Charter Amendment is not approved by the affirmative vote of the holders of a majority of the outstanding shares of our common stock, then the proposed Charter Amendment will not be adopted, and our Charter will not eliminate or limit monetary liability for our officers.
    ******
    The paragraph under the heading “Vote Required to Approve Each Item on the Proxy” on page 86 of the Proxy Statement is hereby amended and restated in its entirety as follows:
    Vote Required to Approve Each Item on the Proxy
    You may vote “for,” “against” or “abstain” on proposals 1, 2, 3, 4 and 5. Abstentions and broker non-votes are included in the determination of the number of shares present at the annual meeting for determining whether a quorum is present at the meeting but are not counted as shares cast. Accordingly, abstentions and broker non-votes, if any, would have no effect on the vote for Proposals 1, 3, 4 and 5, because these Proposals are based on a percentage of the votes that are actually cast at the annual meeting. Abstentions and broker non-votes will have the same effect as votes “Against” Proposal 2.

    Get the next $ALNY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALNY

    DatePrice TargetRatingAnalyst
    3/31/2025$353.00Buy
    Redburn Atlantic
    3/24/2025$280.00 → $328.00Neutral → Overweight
    Analyst
    11/12/2024Peer Perform → Underperform
    Wolfe Research
    10/16/2024Sector Outperform
    Scotiabank
    8/16/2024$198.00 → $370.00Neutral → Buy
    Goldman
    2/16/2024$173.00Buy → Neutral
    Goldman
    2/15/2024Peer Perform
    Wolfe Research
    12/8/2023$171.00Equal Weight
    Wells Fargo
    More analyst ratings

    $ALNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Alnylam Pharma with a new price target

      Redburn Atlantic initiated coverage of Alnylam Pharma with a rating of Buy and set a new price target of $353.00

      3/31/25 8:12:33 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Pharma upgraded by Analyst with a new price target

      Analyst upgraded Alnylam Pharma from Neutral to Overweight and set a new price target of $328.00 from $280.00 previously

      3/24/25 8:23:59 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Pharma downgraded by Wolfe Research

      Wolfe Research downgraded Alnylam Pharma from Peer Perform to Underperform

      11/12/24 7:27:31 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

      OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC is pleased to announce that OXLUMO® (lumasiran) is now funded across Canada through both public and private plans. OXLUMO is an RNA interference (RNAi) therapeutic administered via subcutaneous injection, indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in paediatric and adult patients.1 OXLUMO is the first therapy for PH1 approved in Canada, and among the first medi

      7/2/25 12:30:00 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

      − R&D Organization Positioned to Deliver Next Wave of Transformative RNAi Therapeutics – − Goal of Delivering RNAi Therapeutics to All Major Tissues by 2030 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. Building on the launch of AMVUTTRA® in transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam is entering a new phase of growth, and a combined R&D organization will accelerate pipeline progress by fostering earlier collaboration, faster decision-making,

      6/18/25 10:05:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

      DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Instil's wholly-owned subsidiary dedicated to the development of AXN-2510 ("'2510"), a potentially best-in-class PD-L1xVEGF bispecific antibody for solid tumors prioritizing front-line non-small cell lung cancer (NSCLC). "John's appointment reflects our commitment to assembling world-class leadership to maximize the value of the ‘2510 program for patients and shareholders, and we have benefited greatly fr

      6/11/25 7:00:22 AM ET
      $ALNY
      $TIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $ALNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Reitan Colleen F bought $10,363 worth of shares (36 units at $287.85), sold $8,383 worth of shares (36 units at $232.86) and was granted 775 shares (SEC Form 4)

      4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

      5/12/25 4:05:00 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    SEC Filings

    See more
    • Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

      6/18/25 4:48:38 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

      5/13/25 5:01:36 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Alnylam Pharmaceuticals Inc.

      10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

      5/1/25 8:15:07 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CSO & EVP, Head of Research Fitzgerald Kevin Joseph was granted 7,763 shares, increasing direct ownership by 57% to 21,264 units (SEC Form 4)

      4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

      7/2/25 4:26:48 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Greenstreet Yvonne exercised 50,937 shares at a strike of $118.56 and sold $15,535,784 worth of shares (50,937 units at $305.00) (SEC Form 4)

      4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

      6/3/25 4:10:42 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bonney Michael W exercised 11,250 shares at a strike of $131.21 and sold $3,124,217 worth of shares (11,250 units at $277.71) (SEC Form 4)

      4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

      5/19/25 4:17:09 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

      Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

      4/30/24 1:44:03 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC

      Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling

      9/20/23 2:36:38 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

      Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling

      2/17/23 12:30:09 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Leadership Updates

    Live Leadership Updates

    See more
    • Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

      Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has

      3/5/25 7:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

      As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th

      3/5/24 9:06:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Announces Appointment of Peter Kellogg to Board of Directors

      – Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. "Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to achieving our P5x25 strategy and fulfilling our ambition to become a top-tier biopharmaceutical company," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "His financial expertise and experi

      3/8/23 7:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Financials

    Live finance-specific insights

    See more
    • Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

      − Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise – − Received U.S. Food and Drug Administration (FDA) Approval of AMVUTTRA® (vutrisiran) to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) – − AMVUTTRA ATTR-CM Launch Underway with Strong Progress Across All Early Commercial Indicators – − Approval of Qfitlia™ Represents the First and Only Therapeutic to Treat Hemophilia A or B With or Without Inhibitors and the Sixth Alnylam-Discovered

      5/1/25 8:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

      Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2025 results as well as expectations for the future via conference call on Thursday, May 1, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceuticals A

      4/17/25 8:00:00 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

      − Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source – − Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality of Life in ATTR-CM Population Representative of Today's Patients – – Only Therapeutic Approved in the U.S. to Address Both Cardiomyopathy and Polyneuropathy Manifestations of ATTR Amyloidosis − – Alnylam Offers Multiple Programs to Support Broad and Seamless Patient Access; Majority of Patients Expected to Pay $0 in Out-of-Pocket Costs for AMVUTTRA – – Alnylam to Host Conference Call Today at 6:00 pm ET – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today anno

      3/20/25 5:54:00 PM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

      SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

      11/12/24 9:50:12 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

      SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

      11/8/24 10:34:33 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

      SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

      8/12/24 9:40:06 AM ET
      $ALNY
      Biotechnology: Pharmaceutical Preparations
      Health Care